Results 101 to 110 of about 6,658 (202)

Rucaparib Camsylate [PDF]

, 2020
openaire   +1 more source

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. [PDF]

PLoS One
Deng O, Nepomuceno TDC, Fang B, Welsh EA, Izumi V, Martin RH, George EM, Koomen JM, Monteiro AN, Rix U.   +9 more
europepmc   +1 more source

Use of Rucaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma: A Case Report From a Tertiary Centre in India. [PDF]

Cureus
Arora A, Rastogi S, Tilak A, Ahmed S, Rathore R.   +4 more
europepmc   +1 more source

Maintenance rucaparib after first-line platinum-based chemotherapy in HER2-negative advanced oesophagogastric adenocarcinoma: results from the PLATFORM study. [PDF]

ESMO Open
Gordon A, Fong C, Satchwell L, Cromarty S, Piadel K, Tran A, Begum R, Woodward A, Leamon B, Zhitkov O, Terlizzo M, Hubank M, Proszek P, Pietka G, Peat E, Cartwright E, Davidson M, Das P, Sothi S, Herbertson R, Darby S, Waddell T, Bradshaw A, Rao S, Starling N, Chau I, Cunningham D.   +26 more
europepmc   +1 more source

Plasma-Derived Genomic Instability Status and Rucaparib Outcomes in Metastatic Castration-Resistant Prostate Cancer: TRITON2. [PDF]

JCO Precis Oncol
Abida W, Bryce AH, Chowdhury S, Patnaik A, Overstreet B, Margolis M, Safabakhsh P, Fizazi K.   +7 more
europepmc   +1 more source

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. [PDF]

Future Oncol
Bryce AH, Nash P, Roessler A, Mandair D.
europepmc   +1 more source

A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02. [PDF]

Clin Cancer Res
Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V.   +16 more
europepmc   +1 more source

PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis. [PDF]

Front Oncol
Feng J, Qin X, Mo X.
europepmc   +1 more source

Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System). [PDF]

Curr Oncol
Ahmed Z, Sayyid R, Yazdanpanah O, Samaeekia R, Kalebasty AR, Lee DI, Shahait M.   +6 more
europepmc   +1 more source

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA. [PDF]

Cancers (Basel)
Uccello M, Boussios S, Maï C, Worton H, Bazire A, de Buhren B.   +5 more
europepmc   +1 more source